ZIOP NASDAQ
ZIOPHARM Oncology, Inc.
1W: -3.4%
1M: -25.4%
3M: -41.5%
1Y: -79.6%
3Y: -57.1%
5Y: -84.8%
$0.87
Last traded 2022-01-26 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Income Trends
Revenue
$10K
+0.0% ▲
5Y CAGR: -72.9%
Gross Profit
$0
+0.0% ▲
Operating Income
-$5M
+0.0% ▲
Net Income
-$5M
+0.0% ▲
EPS (Diluted)
$-2.92
+0.0% ▲
EBITDA
-$5M
+0.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2017 | FY2018 | FY2019 | FY2020 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $6M | $146K | $0 | $0 | $10K |
| YoY Growth | -6.9% | -97.7% | -100.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $6M | $146K | $0 | $0 | $0 |
| Gross Margin | 100.0% | 100.0% | — | — | 0.0% |
| R&D Expenses | $45M | $34M | $38M | $53M | $362K |
| SG&A Expenses | $15M | $20M | $20M | $28M | $4M |
| Operating Expenses | $60M | $54M | $58M | $80M | $5M |
| Operating Income | -$54M | -$53M | -$118M | -$80M | -$5M |
| Operating Margin | -850.3% | -36381.5% | — | — | -48120.0% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$54M | -$53M | -$118M | -$80M | -$5M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$54M | -$53M | -$118M | -$80M | -$5M |
| Net Margin | -850.3% | -36381.5% | — | — | -46790.0% |
| EPS (Diluted) | $-0.40 | $-0.37 | $-0.70 | $-0.38 | $-2.92 |
| EBITDA | -$54M | -$53M | -$117M | -$79M | -$5M |
| Shares Outstanding | 137M | 144M | 168M | 210M | 1.60B |